Rapid-onset CBD nasal microemulsion for allergic rhinitis
A patent-pending intranasal CBD microemulsion for rapid allergy relief, designed to be steroid-free and suitable for OTC use. This innovative formulation enhances solubilization and transmucosal penetration, offering fast-acting, localized anti-inflammatory effects.
Overview
Micellae Delivery Systems Inc. presents a breakthrough in allergy relief with a patent-pending intranasal cannabidiol (CBD) microemulsion. Designed for rapid onset, this innovative formulation provides a steroid-free alternative for managing allergic rhinitis. The microemulsion enhances solubilization and transmucosal penetration of CBD, enabling quick and effective anti-inflammatory action. In preclinical studies, its efficacy was comparable to corticosteroids and superior to polyethylene glycol (PEG)-based alternatives, making it suitable for over-the-counter (OTC) use.
Technical specifications
Key features:
- Microemulsion formulation: Thermodynamically stable, featuring ultra-low viscosity and low interfacial tension with sub-100 nm droplets encapsulating CBD.
- Rapid action: Demonstrated fast onset of action in preclinical studies, with significant reduction in eosinophilic inflammation.
- Safety profile: Free from PEG and alcohol, minimizing irritation and supporting a clean-label OTC product.
- Formulation flexibility: Suitable for nasal rinses, sprays, or mists, with potential for modular OTC product lines.
Technology readiness level
This technology is currently at TRL 4, having demonstrated efficacy in preclinical models. The next steps include regulatory submission for Phase 1 studies, in vivo safety and efficacy testing, and GMP-compliant production. Future plans involve optimizing formulation, conducting stability testing, and expanding usability trials for OTC positioning.
About Micellae Delivery Systems Inc.
Micellae Delivery Systems Inc. is a technology-based company that specializes in advanced drug delivery systems designed to improve the solubility and bioavailability of hydrophobic bioactive compounds. Founded as a spinout from the University of Toronto based on 15 years of research, the company developed O2W, a proprietary Self-Microemulsifying Drug Delivery System (SMEDDS). This technology is designed to be free of Polyethylene Glycols (PEGs) and uses food-grade excipients to enhance the performance, onset speed, and safety of formulations. Their platform is adaptable for various dosage forms, including concentrates, powders, and gels, providing a tunable-release profile for high-potency products.
The company primarily serves pharmaceutical, medical, and recreational cannabis producers, helping them create safer, more sustainable, and high-performing products. By solving the challenge of low oral bioavailability in cannabinoids—which typically suffer from poor absorption in the gastrointestinal tract—Micellae’s technology aims to deliver therapeutic effects more efficiently to consumers and patients. The firm actively engages with industry partners to integrate O2W into existing or new product lines, supported by a foundation of academic research, granted patents, and peer-reviewed scientific publications that validate their formulation expertise.
delivered to your inbox.